Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coherus Bio (NQ: CHRS )

1.260 -0.020 (-1.56%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Coherus Bio

< Previous 1 2 3 4 5 6 7 8 9 Next >
Coherus and Junshi Biosciences Receive CRL from FDA for Toripalimab in combination with Gemcitabine and Cisplatin In metastatic nasopharyngeal carcinoma (NPC)
Shanghai Junshi Biosciences and Coherus BioSciences, Inc. (NASDAQ: CHRS) received a complete response letter (CRL) from the U.S. 
Via Benzinga
FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer
Via Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with... 
Via Benzinga
Junshi Biosciences - Coherus Toripalimab Chemo Combo Met Survival Endpoints In Lung Cancer Setting
Via Benzinga
Recap: Coherus BioSciences Q4 Earnings
Coherus BioSciences (NASDAQ:CHRS) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 160 companies hit new 52-week lows. Areas of Significance In Today's 52-Week Lows: Walt Disney (NYSE:DIS) was the largest firm by market cap to set a new... 
Via Benzinga
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2022
Upgrades According to Brookline Capital, the prior rating for Intellia Therapeutics Inc (NASDAQ:NTLA) was changed from Hold to Buy. In the fourth quarter, Intellia Therapeutics... 
Via Benzinga
Coherus BioSciences' Q4 Sales Fall 34% On Lower Udenyca Volume, Prices
Coherus BioSciences Inc's (NASDAQ: CHRS) Q4 net revenue was $73.4 million for Q4 FY21 compared to $110.4 million for the same period in 2020, missing estimates... 
Via Benzinga
Earnings Scheduled For February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
Via Benzinga
The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel... 
Via Benzinga
A Preview Of Coherus BioSciences's Earnings
Coherus BioSciences (NASDAQ:CHRS) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Coherus... 
Via Benzinga
The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More
Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Intra-Cellular Therapies (NASDAQ:ITCI) stock rose 18.79% to $46.52 during Monday's pre-market session. The market value of their outstanding shares is at $3.7... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Biofrontera (NASDAQ:BFRA) stock r... 
Via Benzinga
Coherus BioSciences, inc (CHRS) Q3 2021 Earnings Call Transcript
CHRS earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: Coherus BioSciences Q3 Earnings
Coherus BioSciences (NASDAQ:CHRS) reported its Q3 earnings results on Monday, November 8, 2021 at 04:01 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Week In Review: Two China Affiliated Biopharmas Raise $585 Million In IPOs
LianBio raised $325 million in its Nasdaq IPO at a market capitalization of $1.9 billion to support its drug in-licensings for China. Beijing Clover Biopharma also completed a $260 million IPO in Hong... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Coherus' Udenyca Body Injector At par With Pre-filled syringe
Coherus BioSciences Inc (NASDAQ: CHRS) announced results from a bioequivalence study of Udenyca (pegfilgrastim-cbqv) administered via a proprietary on-body... 
Via Benzinga
Junshi Biosciences, Coherus Share Toripalimab Survival Data In Esophageal Cancer
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced interim results from the Phase 3 JUPITER-06 trial. Related: Coherus,... 
Via Benzinga
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE... 
Via Benzinga
Exposures COVID-19
38 Stocks Moving In Thursday's Mid-Day Session
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares jumped 141% to $1.7950 after dropping 12% on Wednesday. Sonnet BioTherapeutics recently reported its financial... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Sonnet BioTherapeutics (NASDAQ:SONN) shares increased by 97.28% to $1.47 during Thursday's pre-market session. The market value of their outstanding shares is... 
Via Benzinga
The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
See Why Coherus Stock Is Rising After Toripalimab Combination Trial In Lung Cancer
Shanghai Junshi Biosciences Co Ltd and Coherus BioSciences Inc (NASDAQ: CHRS) announced positive interim results from CHOICE-01 Phase 3 trial evaluating... 
Via Benzinga
21 Stocks Moving in Thursday's Pre-Market Session
Gainers Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) shares rose 86.5% to $1.39 in pre-market trading after dropping 12% on Wednesday. Sonnet BioTherapeutics recently... 
Via Benzinga
Week In Review: RemeGen Out-Licenses Rights For HER2 ADC To Seagen In $2.6 Billion Deal
Yantai's RemeGen out-licensed global rights (ex-Asia) for its novel HER2-targeted ADC to Seagen in a $2.6 billion deal. Seagen, an antibody conjugate company, will pay $200 million upfront and up to... 
Via Talk Markets
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.